Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?
Abstract
:1. Introduction
2. Matters Arising
3. Treatment Strategies
4. Early RA Treatment
5. Conclusions
Author Contributions
Conflicts of Interest
References
- Pelechas, E.; Kaltsonoudis, E.; Voulgari, P.V.; Drosos, A.A. Rheumatoid Arthritis. In Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases; Pelechas, E., Ed.; Springer: Cham, Switzerland, 2019; pp. 45–76. [Google Scholar]
- Alamanos, Y.; Drosos, A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 2005, 4, 130–136. [Google Scholar] [CrossRef] [PubMed]
- Alamanos, Y.; Voulgari, P.V.; Drosos, A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. Semin. Arthritis Rheum. 2006, 36, 182–188. [Google Scholar] [CrossRef] [PubMed]
- Dadoun, S.; Zeboulon-Ktorza, N.; Combescure, C.; Elhai, M.; Rozenberg, S.; Gossec, L.; Fautrel, B. Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis. Joint Bone Spine 2013, 80, 29–33. [Google Scholar] [CrossRef] [PubMed]
- Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S.; et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumatol. 1988, 31, 315–324. [Google Scholar] [CrossRef] [PubMed]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., III; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010, 69, 1580–1588. [Google Scholar] [CrossRef] [PubMed]
- Pelechas, E.; Voulgari, P.V.; Drosos, A.A. Golimumab for Rheumatoid Arthritis. J. Clin. Med. 2019, 8, 387. [Google Scholar] [CrossRef] [PubMed]
- Aaltonen, K.J.; Virkki, L.M.; Malmivaara, A.; Konttinen, Y.T.; Nordstrom, D.C.; Blom, M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 2012, 7, e30275. [Google Scholar] [CrossRef]
- Scott, L.J. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 2017, 77, 1865–1879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Papagoras, C.; Drosos, A.A. Abatacept: A biologic immune modulator for rheumatoid arthritis. Expert Opin. Biol. Ther. 2011, 11, 1113–1129. [Google Scholar] [CrossRef]
- Schioppo, T.; Ingegnoli, F. Current perspective on rituximab in rheumatic diseases. Drug Des. Dev. Ther. 2017, 11, 2891–2904. [Google Scholar] [CrossRef]
- O’Shea, J.J.; Schwartz, D.M.; Villarino, A.V.; Gadina, M.; McInnes, I.B.; Laurence, A. The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu. Rev. Med. 2015, 66, 311–328. [Google Scholar] [CrossRef] [PubMed]
- Doiugados, M.; van der Jeijde, D.; Chen, Y.C.; Greenwald, M.; Drescher, E.; Liu, J.; Beattie, S.; Witt, S.; de la Torre, I.; Gaich, C.; et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Ann. Rheum. Dis. 2017, 76, 88–95. [Google Scholar] [CrossRef] [PubMed]
- Smolen, J.S.; Breedveld, F.C.; Burmester, G.R.; Bykerk, V.; Dougados, M.; Emery, P.; Kvien, T.K.; Navarro-Compan, M.V.; Oliver, S.; Schoels, M.; et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann. Rheum. Dis. 2016, 75, 3–15. [Google Scholar] [CrossRef] [PubMed]
- Singh, J.A.; Saag, K.G.; Bridges, S.L., Jr.; Akl, E.; Bannuru, R.R.; Sullivan, M.C.; Vaysbrot, E.; McNaughton, C.; Osani, M.; Shmerling, R.H.; et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016, 68, 1–26. [Google Scholar] [CrossRef] [PubMed]
- Smolen, J.S.; Landewe, R.; Bijlsma, J.; Burmester, G.; Chatzidionysiou, K.; Dougados, M.; Nam, J.; Ramiro, S.; Voshaar, M.; van Vollenhoven, R.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017, 76, 960–977. [Google Scholar] [CrossRef] [PubMed]
- Anderson, J.; Caplan, L.; Yazdany, K.; Robbins, M.L.; Neogi, T.; Michaud, K.; Saag, K.G.; O’Dell, J.R.; Kazi, S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012, 64, 640–647. [Google Scholar] [CrossRef] [PubMed]
- Prevoo, M.L.; van ‘t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheumatol. 1995, 38, 44–48. [Google Scholar] [CrossRef] [PubMed]
- Flouri, I.; Markatseli, T.E.; Voulgari, P.V.; Boki, K.A.; Papadopoulos, I.; Settas, L.; Zisopoulos, D.; Skopouli, F.N.; Iliopoulos, A.; Bertsias, G.K.; et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin. Arthritis Rheum. 2014, 43, 447–457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pope, J.; Combe, B. Unmet needs in the treatment of rheumatoid arthritis. Open J. Rheumatol. Autoimmune Dis. 2013, 3, 65–78. [Google Scholar] [CrossRef]
- De Hair, M.J.H.; Jacobs, J.W.G.; Schoneveld, J.L.M.; van Laar, J.N. Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need. Rheumatology 2017, 57, 1135–1144. [Google Scholar]
- Giacomelli, R.; Afeltra, A.; Alunno, A.; Baldini, C.; Bartoloni-Bocci, E.; Berardicurti, O.; Carubbi, F.; Cauli, A.; Cervera, R.; Ciccia, F.; et al. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun. Rev. 2017, 16, 911–924. [Google Scholar] [PubMed]
- Taylor, P.C.; Moore, A.; Vasilescu, R.; Alvir, J.; Tarallo, M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective. Rheumatol. Int. 2016, 36, 685–695. [Google Scholar] [CrossRef] [PubMed]
- Olsen, I.C.; Lie, E.; Vasilescu, R.; Wallenstein, G.; Strengholt, S.; Kvien, T.K. Assessments of the unmet need in the management of patients with rheumatoid arthritis: Analyses from the NOR-DMARD registry. Rheumatology 2019, 58, 481–491. [Google Scholar] [CrossRef] [PubMed]
- Winthrop, K.L.; Strand, V.; van den Heijde, D.M.; Mease, P.J.; Crow, M.K.; Weinblatt, M.; Bathon, J.M.; Buch, M.H.; Burmester, G.R.; Dougados, M.; et al. The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016. Clin. Exp. Rheumatol. 2016, 34, 69–76. [Google Scholar] [PubMed]
- Drosos, A.A.; Psychols, D.; Andonopoulos, A.P.; Stefanaki-Nikou, S.; Tsianos, E.B.; Moutsopoulos, H.M. Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up. Clin. Rheumatol. 1990, 9, 333–341. [Google Scholar] [CrossRef] [PubMed]
- Drosos, A.A.; Karantanas, A.H.; Psychos, D.; Tsampoulas, C.; Moutsopoulos, H.M. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin. Rheumatol. 1990, 9, 342–345. [Google Scholar] [CrossRef]
- Drosos, A.A.; Georgiou, P.; Politi, E.N.; Voulgari, P.V. D-penicillamine in early rheumatoid arthritis. Clin. Exp. Rheumatol. 1997, 15, 580–581. [Google Scholar]
- Drosos, A.A.; Voulgari, P.V.; Papadopoulos, I.A.; Politi, E.N.; Georgiou, P.E.; Zikou, A.K. Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clin. Exp. Rheumatol. 1998, 16, 695–701. [Google Scholar]
- Lyman, G.H.; Zon, R.; Harvey, R.D.; Schilsky, R.L. Rationale, Opportunities, and Reality of Biosimilar Medications. N. Engl. J. Med. 2018, 378, 2036–2044. [Google Scholar] [CrossRef]
- Pelechas, E.; Voulgari, P.V.; Drosos, A.A. ABP 501 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 2018, 18, 317–322. [Google Scholar] [CrossRef]
- Pelechas, E.; Drosos, A.A. Etanercept biosimilar SB-4. Expert Opin. Biol. Ther. 2019, 19, 173–179. [Google Scholar] [CrossRef] [PubMed]
- Mueller, R.B.; Spaeth, M.; von Restorff, C.; Ackermann, C.; Schulze-Koops, H.; von Kempis, J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J. Clin. Med. 2019, 8, 302. [Google Scholar] [CrossRef] [PubMed]
- Taylor, P.C.; Balsa Criado, A.; Mongey, A.B.; Avouac, J.; Marotte, H.; Mueller, R.B. How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. J. Clin. Med. 2019, 8, 515. [Google Scholar] [CrossRef] [PubMed]
- Fleischmann, R.; Tongbram, V.; van Vollenhoven, R.; Tang, D.H.; Chung, J.; Collier, D.; Urs, S.; Ndirangu, K.; Wells, G.; Pope, J. Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. RMD Open 2017, 3, e000371. [Google Scholar] [CrossRef] [PubMed]
- Peper, S.M.; Lew, R.; Mikuls, T.; Brophy, M.; Rybin, D.; Wu, H.; O’Dell, J. Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. Arthritis Care Res. 2017, 69, 1467–1472. [Google Scholar] [CrossRef] [Green Version]
- Quach, L.T.; Chang, B.H.; Brophy, M.T.; Soe Thwin, S.; Hannagan, K.; O’Dell, J.R. Rheumatoid arthritis triple therapy compared with etanercept: Difference in infectious and gastrointestinal adverse events. Rheumatology 2017, 56, 378–383. [Google Scholar] [CrossRef]
- Kaltsonoudis, E.; Pelechas, E.; Voulgari, P.V.; Drosos, A.A. Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center. Semin. Arthritis Rheum. 2019, 48, 597–602. [Google Scholar] [CrossRef]
- Boers, M.; Verhoeven, A.C.; Markusse, H.M.; van de Laar, M.A.; Westhovens, R.; van Denderen, J.C.; van Zeben, D.; Dijkmans, B.A.; Peeters, A.J.; Jacobs, P.; et al. Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with Sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350, 309–318. [Google Scholar] [CrossRef]
- Landewe, R.B.; Boers, M.; Verhoeven, A.C.; Westhovens, R.; van de Laar, M.A.; Markusse, H.M.; van Denderen, J.C.; Westedt, M.L.; Peeters, A.J.; Dijkmans, B.A.; et al. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheumatol. 2002, 46, 347–356. [Google Scholar] [CrossRef]
- Van Tuyl, L.H.; Boers, M.; Lems, W.F.; Landewé, R.B.; Han, H.; van der Linden, S.; van de Laar, M.; Westhovens, R.; Van Denderen, J.C.; Westedt, M.L.; et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69, 807–812. [Google Scholar] [CrossRef]
- Poppelaars, P.B.; van Tuyl, L.H.D.; Boers, M. Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Ann. Rheum. Dis. 2019, 78, 586–589. [Google Scholar] [CrossRef] [PubMed]
- Van Vollenhoven, R.F.; Geborek, P.; Forslind, K.; Albertsson, K.; Ernestam, S.; Petersson, I.F.; Chatzidionysiou, K.; Bratt, J.; Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2010, 379, 1712–1720. [Google Scholar] [CrossRef]
- O’Dell, J.R.; Mikuls, T.R.; Taylor, T.H.; Ahluwalia, V.; Brophy, M.; Warren, S.R.; Lew, R.A.; Cannella, A.C.; Kunkel, G.; Phibbs, C.S.; et al. Therapies for active rheumatoid arthritis after methotrexate failure. N. Eng. J. Med. 2014, 369, 307–318. [Google Scholar] [CrossRef] [PubMed]
- Moreland, L.W.; O’Dell, J.R.; Paulus, H.E.; Curtis, J.R.; Bathon, J.M.; St Clair, E.W.; Bridges, S.L., Jr.; Zhang, J.; McVie, T.; Howard, G.; et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early/Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2012, 64, 2824–2835. [Google Scholar] [CrossRef] [PubMed]
- Bathon, J.M.; McMahon, D.J. Making rational treatment decisions in rheumatoid arthritis when methotrexate fails. N. Engl. J. Med. 2013, 369, 384–385. [Google Scholar] [CrossRef] [PubMed]
- European Medicines Agency. Available online: https://www.ema.europa.eu/en/search/search (accessed on 31 March 2019).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Drosos, A.A.; Pelechas, E.; Voulgari, P.V. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? J. Clin. Med. 2019, 8, 1237. https://doi.org/10.3390/jcm8081237
Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs? Journal of Clinical Medicine. 2019; 8(8):1237. https://doi.org/10.3390/jcm8081237
Chicago/Turabian StyleDrosos, Alexandros A., Eleftherios Pelechas, and Paraskevi V. Voulgari. 2019. "Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?" Journal of Clinical Medicine 8, no. 8: 1237. https://doi.org/10.3390/jcm8081237